เอกสารอ้างอิง

FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

Daraxonrasib versus chemotherapy in previously treated metastatic pancreatic cancer (RASolute 302)

Daraxonrasib in previously treated RAS-mutant non-small-cell lung cancer: phase 1/2 results

RASolute 302: Phase 3 study of daraxonrasib vs. standard of care chemotherapy in previously treated metastatic PDAC

RASolve 301: Study of daraxonrasib in patients with RAS mutated NSCLC

RMC-6236-001: First-in-human study of RMC-6236 in RAS-mutant solid tumors

เว็บไซต์ทางการของ Revolution Medicines

ระบบค้นหาการทดลองทางคลินิกของ Revolution Medicines

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib

Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer